Conclusion

The authors note that the increasing focus on cardiovascular safety has necessitated large prospective post-marketing studies of new diabetes agents. Increasing understanding of the “molecular underpinnings of diabetes and HF” are leading to the development of “rational drug targets with the goal of reducing myocardial insulin resistance and oxidative stress.” The authors state that the SGLT-2 inhibitors raise “the exciting possibility of improved outcomes in HF.” However, further research is needed to determine “whether these agents will improve disease-specific symptoms, quality of life, ejection fraction, and other important clinical endpoints.”

References


Continue Reading

1.      DeFilippis EM, Givertz MM. Treating diabetes in patients with heart failure: moving from risk to benefit. Curr Heart Fail Rep. 2016;13(3):111-118.

2.      Qi Y, Zhu Q, Zhang K, et al. Activation of Foxo1 by insulin resistance promotes cardiac dysfunction and β-myosin heavy chain gene expression. Circ Heart Fail. 2015;8(1):198-208.

3.      Zhang L, Jaswal JS, Ussher JR, et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail. 20131;6(5):1039-1048.

4.      Ansley DM, Wang B. Oxidative stress and myocardial injury in the diabetic heart. J Pathol. 2013;229(2):232-241.

5.      Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108(23):2941-2948.

6.      Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.

7.      Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-1588.

8.      White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.

9.      Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-2076.

10.  Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 ;373(3):232-242.

11.  Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic  drug therapy. Lancet. 2015;385(9982):2107-2117.

12.  Bhatt DL, Cavender MA. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? JACC Heart Fail. 2014;2(6):583-585.

13.  Son JW, Kim S. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes Metab J. 2015;39(5):373-383.

14.  Nathanson D, Frick M, Ullman B, Nyström T. Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. Diabetol Metab Syndr. 2016;8:5.

15.  Nathanson D, Ullman B, Löfström U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926-935.

16.  Chen WR, Shen XQ, Zhang Y, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016;52(3):516-526.

17.  Margulies KB, Anstrom KJ, Hernandez AF, et al. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction:  design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail. 2014 ;7(4):673-679.

18.  Pfeffer MA, Claggett B, Probstfield JL. Lixisenatide in type 2 diabetes and acute coronary syndrome. N Engl J Med. 2016;374(11):1095-1096.

19.  Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.